Published in Br J Cancer on May 01, 1999
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J (2006) 1.93
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer (2008) 1.50
Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia (2007) 1.49
A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene (2009) 1.35
Angiogenesis in melanoma. Semin Oncol (2007) 1.30
Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol (2002) 1.27
TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res (2012) 1.20
MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis (2009) 1.20
Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer (2001) 1.09
Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol (2008) 1.08
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia (2007) 1.07
A novel organotypic model mimics the tumor microenvironment. Am J Pathol (2009) 1.01
Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem (2012) 0.97
Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res (2011) 0.92
Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression. J Biol Chem (2011) 0.92
Membrane-type-3 matrix metalloproteinase (MT3-MMP) functions as a matrix composition-dependent effector of melanoma cell invasion. PLoS One (2011) 0.91
Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Transl Oncol (2009) 0.91
Actin-associated protein palladin promotes tumor cell invasion by linking extracellular matrix degradation to cell cytoskeleton. Mol Biol Cell (2014) 0.91
Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis (2004) 0.91
Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor. Neoplasia (2012) 0.89
Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem (2006) 0.89
Angiogenesis and progression in human melanoma. Dermatol Res Pract (2010) 0.88
Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One (2011) 0.88
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs (2007) 0.88
Overexpression of MMP13 is associated with clinical outcomes and poor prognosis in oral squamous cell carcinoma. ScientificWorldJournal (2014) 0.88
Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. Am J Pathol (2001) 0.86
Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. J Cell Physiol (2013) 0.86
Expression of collagenase-1 (MMP-1), collagenase-3 (MMP-13) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in laryngeal squamous cell carcinomas. Eur Arch Otorhinolaryngol (2003) 0.84
A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem (2014) 0.84
Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion. Adv Exp Med Biol (2015) 0.83
Heparanase mRNA expression and point mutation in hepatocellular carcinoma. World J Gastroenterol (2004) 0.83
Elastin-derived peptides enhance melanoma growth in vivo by upregulating the activation of Mcol-A (MMP-1) collagenase. Br J Cancer (2010) 0.82
The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Matrix Biol (2015) 0.79
Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett (2011) 0.77
Tpl2 knockout keratinocytes have increased biomarkers for invasion and metastasis. Carcinogenesis (2013) 0.77
MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype. Virchows Arch (2005) 0.77
Paclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafish. Proc Natl Acad Sci U S A (2016) 0.76
Correlations of polymorphisms in matrix metalloproteinase-1, -2, and -7 promoters to susceptibility to malignant gliomas. Asian J Neurosurg (2016) 0.75
CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. Front Oncol (2015) 0.75
Role of matrix metalloproteinase 13 gene expression in the evaluation of radiation response in oral squamous cell carcinoma. J Carcinog (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg (1970) 12.72
Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res (1985) 10.76
A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (1994) 9.31
Matrix metalloproteinases: a review. Crit Rev Oral Biol Med (1993) 9.03
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 6.52
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem (1995) 5.57
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol (1997) 4.09
H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem (1988) 4.06
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem (1994) 3.64
Biochemical characterization of human collagenase-3. J Biol Chem (1996) 3.52
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res (1990) 2.40
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci (1997) 2.28
Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J (1993) 2.28
The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem (1997) 2.09
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Matrix metalloproteinases in skin. Exp Dermatol (1997) 1.84
Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res (1998) 1.83
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol (1997) 1.66
TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer (1998) 1.58
Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J Clin Invest (1993) 1.56
Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J (1998) 1.48
Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J Clin Invest (1992) 1.45
Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry (1997) 1.35
Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem (1996) 1.35
Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol (1997) 1.34
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res (1997) 1.25
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst (1989) 1.23
Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res (1998) 1.21
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol (1994) 1.21
Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst (1994) 1.19
Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem (1997) 1.17
TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res (1996) 1.17
Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol (1997) 1.16
Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol (1997) 1.15
Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol (1996) 1.13
A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol (1996) 1.12
Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J Cell Biochem (1992) 1.12
Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer (1997) 1.10
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol (1994) 1.07
The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res (1995) 1.06
Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res (1993) 1.03
Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. J Biol Chem (1995) 1.01
Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta (1997) 0.99
Human TIMP-3 is expressed during fetal development, hair growth cycle, and cancer progression. J Histochem Cytochem (1998) 0.98
Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase. Int J Cancer (1990) 0.95
TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer (1997) 0.94
Effects of 12-O-tetradecanoylphorbol 13-acetate on the production of mRNAs for human tissue-type plasminogen activator. Eur J Biochem (1983) 0.94
Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer (1996) 0.92
Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol (1996) 0.85
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med (1987) 4.35
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol (1988) 4.34
Ulex europaeus I lectin as a marker for vascular endothelium in human tissues. Lab Invest (1982) 3.29
Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest (1987) 2.74
Growth factors in the extracellular matrix. FASEB J (1997) 2.71
Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol (1986) 2.44
Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev (1999) 2.22
Dimeric character of fibronectin, a major cell surface-associated glycoprotein. Biochem Biophys Res Commun (1977) 2.18
Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol (1994) 2.15
Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment. J Exp Med (1981) 2.10
Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem (1987) 2.05
Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell (2000) 2.01
Matrilysin expression and function in airway epithelium. J Clin Invest (1998) 1.94
Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci U S A (2001) 1.83
Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem (1996) 1.79
Active and latent forms of transforming growth factor beta activity in synovial effusions. J Exp Med (1989) 1.77
Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol (1996) 1.72
Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol (1989) 1.70
Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech (2001) 1.70
Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem (1991) 1.68
Transforming growth factors and control of neoplastic cell growth. J Cell Biochem (1987) 1.67
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol (1997) 1.66
Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII. Cell (1976) 1.64
Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem (1995) 1.61
Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res (1989) 1.55
Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem (1992) 1.50
Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J (1996) 1.50
Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J (1998) 1.48
Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Adv Cancer Res (1998) 1.48
Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol (1996) 1.44
Angiosarcoma. A rare secondary malignancy after breast cancer treatment. Eur J Dermatol (1999) 1.39
MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology (1999) 1.39
Impaired migration and delayed differentiation of pancreatic islet cells in mice lacking EGF-receptors. Development (2000) 1.38
Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene (2000) 1.37
Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain. J Biol Chem (2000) 1.36
The cellular response to induction of the p21 c-Ha-ras oncoprotein includes stimulation of jun gene expression. EMBO J (1989) 1.35
Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem (1996) 1.35
Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol (1997) 1.34
Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res (1986) 1.32
Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis. Int J Cancer (1982) 1.31
Murine sarcoma growth factors affect the growth and morphology of cultured mouse epithelial cells. J Cell Physiol (1980) 1.30
Direct association of fibronectin and actin molecules in vitro. J Cell Biol (1980) 1.28
Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol (1997) 1.26
Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J Biol Chem (1998) 1.24
Fibroblast surface antigen (SF): molecular properties, distribution in vitro and in vivo, and altered expression in transformed cells. J Supramol Struct (1976) 1.23
Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci (2001) 1.23
Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J (2001) 1.22
Interaction of viral envelope glycoproteins with fibronectin. Infect Immun (1983) 1.21
Transforming growth factor beta regulation of cell proliferation. J Cell Physiol Suppl (1987) 1.18
Epsin 3 is a novel extracellular matrix-induced transcript specific to wounded epithelia. J Biol Chem (2001) 1.18
Distribution of a major surface-associated glycoprotein, fibronectin, in cultures of adherent cells. J Supramol Struct (1977) 1.18
Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res (1992) 1.14
1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ (2000) 1.14
Enhanced expression of human metalloelastase (MMP-12) in cutaneous granulomas and macrophage migration. J Invest Dermatol (1999) 1.12
Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J Cell Biochem (1992) 1.12
Independent promoters regulate the expression of two amino terminally distinct forms of latent transforming growth factor-beta binding protein-1 (LTBP-1) in a cell type-specific manner. J Biol Chem (1999) 1.12
Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol (1999) 1.10
The cellular target for the plasminogen activator, urokinase, in human fibroblasts - 66 000 dalton protein. Biochim Biophys Acta (1982) 1.09
Interstitial collagenase is expressed by keratinocytes that are actively involved in reepithelialization in blistering skin disease. J Invest Dermatol (1995) 1.05
Dose effects of transfected c-Ha-rasVal 12 oncogene in transformed cell clones. Exp Cell Res (1987) 1.04
Pachydermoperiostosis: analysis of the connective tissue abnormality in one family. J Am Acad Dermatol (1994) 1.04
Causes and effects of the chronic inflammation in venous leg ulcers. Acta Derm Venereol Suppl (Stockh) (2000) 1.04
Gremlin localization and expression levels partially differentiate idiopathic interstitial pneumonia severity and subtype. J Pathol (2008) 1.02
Interaction of fibronectin with complement component C3. Scand J Immunol (1983) 1.01
Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. J Biol Chem (1995) 1.01
Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol (2001) 1.00
Extracellular matrix proteins characterize human tumor cell lines. Int J Cancer (1981) 1.00
Diagnostic application of monoclonal antibodies to intermediate filaments. Ann N Y Acad Sci (1985) 0.99
Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol (1998) 0.98
Human TIMP-3 is expressed during fetal development, hair growth cycle, and cancer progression. J Histochem Cytochem (1998) 0.98
Enhanced expression of interstitial collagenase, stromelysin-1, and urokinase plasminogen activator in lesions of dermatitis herpetiformis. J Invest Dermatol (1995) 0.97
Left ventricular calcification following resuscitation. J Intern Med (2000) 0.97
Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines. J Invest Dermatol (2000) 0.97
Promoter characterization of the human and mouse epilysin (MMP-28) genes. Gene (2001) 0.96
Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol (2000) 0.96
Isolation of an actin-binding fragment of fibronectin. Biochem J (1981) 0.95
Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer (2001) 0.94
Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci (2004) 0.94
Rapid membrane changes in mouse epithelial cells after exposure to epidermal growth factor. J Ultrastruct Res (1981) 0.94
Cutis laxa in hereditary gelsolin amyloidosis. Br J Dermatol (2005) 0.93
Recombinant latent transforming growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release. J Biol Chem (1998) 0.93
Integrins in human cells and tumors. Cell Differ Dev (1990) 0.92
Keratin filaments of mouse epithelial cells are rapidly affected by epidermal growth factor. J Cell Biol (1981) 0.92
Fibronectin and the pericellular matrix of normal and transformed adherent cells. Ann N Y Acad Sci (1978) 0.91
Fibroblast surface antigen (SF): the external glycoprotein lost in proteolytic stimulation and maligant transfromation. Int J Cancer (1976) 0.91
Ovarian thecal cells produce transforming growth factor-beta which can regulate granulosa cell growth. Endocrinology (1987) 0.90
Cytoskeleton and pericellular matrix organization of pure adult human keratinocytes cultured from suction-blister roof epidermis. J Cell Sci (1982) 0.90
Family dynamics of families with mental health problems in Finland. J Adv Nurs (1997) 0.90